Regulus Therapeutics (NASDAQ:RGLS) Rating Reiterated by HC Wainwright

Regulus Therapeutics (NASDAQ:RGLS)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They presently have a $9.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 303.59% from the stock’s previous close.

Other research analysts have also recently issued research reports about the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of Regulus Therapeutics in a report on Monday, March 18th. StockNews.com began coverage on shares of Regulus Therapeutics in a report on Tuesday, April 16th. They issued a “sell” rating for the company. SVB Leerink began coverage on shares of Regulus Therapeutics in a report on Monday, March 18th. They set an “outperform” rating and a $6.00 target price for the company. Wells Fargo & Company raised their target price on shares of Regulus Therapeutics from $2.00 to $3.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 13th. Finally, Canaccord Genuity Group reduced their target price on shares of Regulus Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, March 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Regulus Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $7.25.

Regulus Therapeutics Stock Down 8.2 %

NASDAQ:RGLS opened at $2.23 on Monday. Regulus Therapeutics has a 52 week low of $1.08 and a 52 week high of $3.79. The firm has a 50 day moving average of $2.34 and a 200 day moving average of $1.69. The stock has a market capitalization of $145.98 million, a price-to-earnings ratio of -1.40 and a beta of 1.59.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.40). As a group, analysts expect that Regulus Therapeutics will post -0.52 EPS for the current year.

Institutional Trading of Regulus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RGLS. Vivo Capital LLC acquired a new stake in Regulus Therapeutics during the first quarter valued at $14,400,000. CVI Holdings LLC acquired a new stake in Regulus Therapeutics during the first quarter valued at $4,050,000. FMR LLC grew its position in Regulus Therapeutics by 32.4% during the third quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock valued at $4,033,000 after buying an additional 716,000 shares during the period. Finally, Victory Capital Management Inc. grew its position in Regulus Therapeutics by 16.5% during the fourth quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock valued at $348,000 after buying an additional 38,529 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.